Biogen, Inc.

( )
BIIB After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
GILDGilead Sciences, Inc. 1.28%63.431.0%$435.37m
AMGNAmgen, Inc. -0.36%236.751.3%$418.05m
BIIBBiogen, Inc. 0.32%288.101.4%$366.81m
ILMNIllumina, Inc. 0.81%331.003.5%$323.28m
VRTXVertex Pharmaceuticals, Inc. 0.27%234.611.9%$274.89m
REGNRegeneron Pharmaceuticals, Inc. -1.26%359.142.6%$231.10m
EXASEXACT Sciences Corp. 10.55%94.9624.0%$230.33m
ALXNAlexion Pharmaceuticals, Inc. -1.43%111.402.0%$170.24m
INCYIncyte Corp. -0.22%78.482.5%$128.85m
AAgilent Technologies, Inc. 0.57%90.121.6%$124.56m
SRPTSarepta Therapeutics, Inc. -3.79%118.3314.6%$110.92m
BMRNBioMarin Pharmaceutical, Inc. 0.05%87.594.3%$106.70m
BLUEbluebird bio, Inc. -2.11%93.8014.2%$93.34m
SGENSeattle Genetics, Inc. 2.79%111.706.1%$92.29m
ITCIIntra-Cellular Therapies, Inc. 0.35%25.529.0%$86.96m

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.